Low heart rate variability (HRV) predicts higher risk of cardiovascular events including myocardial infarction
Summary
HRV reflects autonomic nervous system balance and has been studied as a cardiovascular risk marker since the 1980s. Meta-analyses of prospective cohort studies find that lower HRV is associated with ~30–50% increased risk of cardiac events and all-cause mortality, with the strongest and most consistent signal in post-MI populations. In general/healthy populations the association is weaker, more heterogeneous, and attenuated after adjustment for established risk factors. HRV is not endorsed as a routine risk-stratification tool by ACC/AHA or ESC guidelines for primary prevention; its prognostic value beyond standard risk scores (e.g. ASCVD, SCORE2) is modest. Consumer wearable HRV measurements add further noise and have not been validated against hard cardiac endpoints. The directional claim (low HRV → higher CV risk) is well-replicated; the magnitude and clinical actionability are contested.
Five-score assessment
Scope
- Using consumer-wearable HRV as a standalone clinical diagnostic
- Claim that raising HRV via training/supplements reduces cardiac events
- Precise individual-level risk prediction beyond standard risk calculators
Evidence sources
Supporting (2)
-
Meta-analysis of prospective cohorts found low HRV associated with ~32–45% increased risk of first cardiovascular event in populations without known CVD.
-
Systematic review concluded reduced HRV is a consistent independent predictor of mortality and arrhythmic events following myocardial infarction.
Neutral / context (2)
-
Standards document endorsed HRV as a research/risk marker post-MI and in diabetic neuropathy but noted insufficient evidence for routine general-population screening.
-
Overview confirms lower HRV tracks with cardiovascular and all-cause mortality risk while cautioning that norms, measurement methods, and clinical thresholds remain poorly standardized.